Current Report Filing (8-k)
April 28 2020 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
April 27, 2020
Citius Pharmaceuticals, Inc.
(Exact name of registrant as specified in its
charter)
Nevada
(State or other jurisdiction of incorporation)
333-206903
|
|
27-3425913
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
11 Commerce Drive, 1st Floor, Cranford,
NJ
|
|
07016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's
telephone number, including area code (908) 967-6677
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on
which registered
|
Common stock, $0.001 par value
|
|
CTXR
|
|
The Nasdaq Capital Market
|
Warrants to purchase common stock
|
|
CTXRW
|
|
The Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Material Information.
On April 27, 2020, Citius Pharmaceuticals, Inc. issued a press release
to announce that it had submitted to the U.S. Food and Drug Administration a pre-IND meeting request under the FDA’s Coronavirus
Treatment Acceleration Program for a novel stem cell therapy for acute respiratory distress syndrome (ARDS). A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: April 28, 2020
|
CITIUS PHARMACEUTICALS, INC.
|
|
|
|
/s/ Myron Holubiak
|
|
Myron
Holubiak
President and Chief Executive Officer
|
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Apr 2023 to Apr 2024